Epigenetics in diabetic cardiomyopathy

Xiaozhu Ma,Shuai Mei,Qidamugai Wuyun,Li Zhou,Dating Sun,Jiangtao Yan

DOI: https://doi.org/10.1186/s13148-024-01667-1

2024-04-06

Clinical Epigenetics

Abstract:Diabetic cardiomyopathy (DCM) is a critical complication that poses a significant threat to the health of patients with diabetes. The intricate pathological mechanisms of DCM cause diastolic dysfunction, followed by impaired systolic function in the late stages. Accumulating researches have revealed the association between DCM and various epigenetic regulatory mechanisms, including DNA methylation, histone modifications, non-coding RNAs, and other epigenetic molecules. Recently, a profound understanding of epigenetics in the pathophysiology of DCM has been broadened owing to advanced high-throughput technologies, which assist in developing potential therapeutic strategies. In this review, we briefly introduce the epigenetics regulation and update the relevant progress in DCM. We propose the role of epigenetic factors and non-coding RNAs (ncRNAs) as potential biomarkers and drugs in DCM diagnosis and treatment, providing a new perspective and understanding of epigenomics in DCM.

oncology,genetics & heredity

What problem does this paper attempt to address?

This paper mainly discusses the pathogenic mechanism of diabetic cardiomyopathy (DCM), a serious complication, especially its association with epigenetics. DCM is caused by abnormal glucose and lipid metabolism, leading to impaired cardiac function, initially manifested as diastolic dysfunction and later progressing to systolic dysfunction. Although various factors such as hyperglycemia and insulin resistance are known to be involved in its development, the exact pathogenesis of DCM is not fully understood.

The article points out that epigenetics, including DNA methylation, histone modifications, and non-coding RNA, play a key role in the development of DCM. With the advancement of high-throughput technologies, the understanding of these epigenetic regulatory mechanisms continues to deepen, which is helpful in developing potential therapeutic strategies. The paper reviews how DNA methylation affects gene expression, such as inhibiting transcription by altering chromatin states; the role of dynamic balance of histone modifications, such as acetylation and methylation, in gene expression regulation; and how non-coding RNAs (such as lncRNAs and miRNAs) participate in gene expression regulation, affecting the progression of diseases.

The paper also specifically discusses the effects of DNA methylation level changes on genes such as JunD, SERCA2a, and GPX1 in DCM, the role of histone modifications such as acetylation and deacetylases in oxidative stress, inflammation, and cell differentiation, and how lncRNAs such as TINCR, DACH1, and MALAT1 participate in the progression of DCM by regulating inflammation response and cell death-related pathways.

In conclusion, this paper aims to provide theoretical support for the discovery of new diagnostic biomarkers and therapeutic targets by deepening the understanding of the epigenetic mechanisms of DCM.